Nicolas Stocker

CNS myeloma is a challenging and rare diagnosis, and there's not much data to guide us on the best management. The NCCN guidelines have been updated to include recommendations for diagnosis and management on this entity, and @crdangelo9 led an effort to put this in manuscript form!

2026 Dyslipidemia Guidelines: Key Updates in Cardiovascular Prevention On March 13, 2026, the ACC/AHA Multisociety Guideline on the Management of Dyslipidemia was released, replacing the 2018 cholesterol guideline. The update broadens the focus from cholesterol alone to overall dyslipidemia, including LDL-C, triglycerides, and emerging markers like lipoprotein(a), with a central goal: earlier and more personalized prevention of ASCVD. Major Highlights 1. New Risk Calculator The PREVENT-ASCVD risk equation replaces the older pooled cohort equations for adults 30–79. It often estimates lower and more accurate risk, and also introduces 30-year risk assessment for younger adults. 2. LDL-C Targets Return Clear lipid goals are reintroduced: •<100 mg/dL for borderline/intermediate risk •<70 mg/dL for high risk •<55 mg/dL for very high risk The principle: “lower for longer” to reduce lifetime exposure to atherogenic lipids. 3. Routine Lp(a) Testing For the first time, Lp(a) measurement at least once in a lifetime is recommended for all adults to identify genetic cardiovascular risk. 4. Greater Role for CAC Scoring Coronary artery calcium (CAC) scoring is emphasized for decision-making. A CAC score of 0 may delay statins, while higher scores strongly support treatment. 5. Earlier and Broader Treatment Statins and other therapies (ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran) are recommended earlier in high-risk individuals, including those with diabetes, CKD, or strong family history. 6. Lifestyle Still Comes First Healthy diet patterns, regular physical activity, and weight control remain the foundation of dyslipidemia management. The Big Picture The 2026 guideline emphasizes earlier risk detection, lower lipid targets, and lifelong prevention—aiming to reduce cumulative lipid exposure and ultimately prevent atherosclerotic cardiovascular disease before it develops.

🔥 Apixaban beats rivaroxaban with lower risks of clinically lower bleeding! 🩺 The nephrologist always knew this. The cardiologists, GI specialists and surgeons may need to adjust their practices! nejm.org/doi/full/10.10…

Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy astctjournal.org/article/S2666-…

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 meetings.asco.org/abstracts-pres… #NCT04108624 #mmsm #mmMRD

Solid #OrganTransplant recipients with a history of pretransplant #cancer had higher risks of developing posttransplant cancers of the same type, including breast, lung, kidney, urinary bladder, liver, colorectal, and melanoma. ja.ma/4s7u4dT

Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma | JCO Oncology Advances ascopubs.org/doi/10.1200/OA…

Earlier Use of Bispecific Antibodies in Multiple Myeloma: Current Data and Remaining Questions dailynews.ascopubs.org/do/earlier-use…

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026 in: Journal of the National Comprehensive Cancer Network Volume 24 Issue 3 (2026) jnccn.org/view/journals/…

👉👉Delighted to share our recent editorial on what is the meaning of Cure in the context of CLL. An important topic in the current era of excellent targeted therapy options @Hemasphere_EHA @UTMDAnderson pmc.ncbi.nlm.nih.gov/articles/PMC12…

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism | New England Journal of Medicine nejm.org/doi/full/10.10…

An important CLL message: More treatment time is not always more benefit. Fixed-duration venetoclax combinations were noninferior to continuous ibrutinib for 3-year PFS in previously untreated disease. @NEJM @VincentRK @Dr_AmerZeidan @kirkizlar @mbeksac56 @OncoAlert @OncBrothers @OncoAlert

Current treatment algorithm: diffuse large B cell lymphoma | Blood Cancer Journal share.google/7HdCdx4MKaXBq6…

Causes of excess non-lymphoma death in 58,000 patients with DLBCL diagnosed during 1997-2020 and followed for up to 25 years | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions onlinelibrary.wiley.com/doi/epdf/10.10…

MajesTEC-3: Redefining what’s possible in multiple myeloma #mmsm @mahrefat @HadidiSamer @utswcancer @TheIACH ➡️ chi.scholasticahq.com/article/158751… “The MajesTEC-3 trial represents a landmark achievement in MM therapeutics, joining the growing body of evidence that long-term disease control and potentially, cure, is within reach for many patients.”

🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊 🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications 💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban nejm.org/doi/full/10.10…

Apixaban vs Rivaroxaban in acute VTE 👇 • COBRRA trial (NEJM 2026) • Bleeding: 3.3% vs 7.1% • RR 0.46 • ≈ 54% less bleeding Both DOACs effective, but Apixaban shows lower bleeding risk, especially in elderly or high-bleeding-risk patients. #MVOnco #Thrombosis #MedEd

Teclistamab in RRMM with Renal Impairment Real-world data from the USMIRC multi-institutional study #mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @US_HMC @oncodaily @MedwatchKate @Larvol mdpi.com/2072-6694/18/5…